Data from Trial in Advanced PD Patients Using Levodopa-Carbidopa Intestinal Gel


(March 4, 2015) - Continuous dosing via a levodopa-carbidopa intestinal gel (LCIG, now carbidopa and levodopa enteral suspension in the U.S) directly into the small intestine may be the key to reducing the motor complications associated with long-term levodopa use. In the current issue of the Journal of Parkinson’s Disease, researchers report on the safety and efficacy of LCIG therapy over a one-year period. Read more…

Click for a printer friendly version

Back to top